Hanmi said that MD Anderson Cancer Center has presented the development of its investigator-led phase 2 clinical trial exploring the possibility of further expanding the indication for Poziotinib, a non-small-cell lung cancer (NSCLC) treatment.
|Hanmi headquarters in Bangi-dong, eastern Seoul.|
The U.S. hospital presented the results of the research at the World Conference on Lung Cancer held in Barcelona, Spain, from Sept. 6-9.
The investigator's clinical findings presented at the conference include the effects of Poziotinib in patients with exon 18 mutation and Tagrisso-resistant patients with NSCLC, as well as existing NSCLC patients with exon 20 mutations.
The abstracts of interest include "activity of Poziotinib and other second-generation quinazolines epidermal growth factor receptor (EFGR) tyrosine kinase inhibitors (TKI) in atypical exon 18 and acquired osimertinib resistance mutants," and "identification of mechanisms of acquired resistance to Poziotinib in EGFR exon 20 Mutant NSCLC."
"There continues to be investigator interest in Poziotinib's unique characteristics to address NSCLC mutations, including exon 20 and other mutations, which have limited or no treatment options," said Francois Lebel, chief medical officer of Spectrum Pharmaceuticals, Hanmi's U.S. partner.
The data presented at the conference by the company's scientific collaborators at MD Anderson further expand the body of evidence supporting Poziotinib's role in lung cancer and help the company gain new insights into its full potential, Lebel added.
Spectrum Pharmaceutical President and CEO Joe Turgeon also said, "NSCLC patients with exon 20 insertion mutations have a poor prognosis and very limited treatment options. The company is diligently developing Poziotinib and look forward to topline results from cohort 1 of its phase 2 study in the fourth quarter."